LifeMD Announces Agreement For Its Pharmacies To Directly Dispense, Ship Eli Lilly's Self-Pay GLP-1 Medicines

LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD's affiliated pharmacy to directly dispense and ship Lilly's self-pay GLP-1 medicines, including Zepbound® (tirzepatide) and Foundayo® (orforglipron), to eligible patients across the United States.

Under the arrangement, eligible patients prescribed a Lilly medication by a LifeMD-affiliated healthcare provider following an independent clinical evaluation can purchase that medication at Lilly's established self-pay price directly through LifeMD. Prescriptions will be fulfilled and shipped by LifeMD's licensed mail-order pharmacy, creating a seamless patient experience from consultation and prescribing to fulfillment and home delivery. The program includes both Zepbound® and Foundayo®. Lilly and LifeMD will continue to explore opportunities to expand access to additional medicines in the future.